Evaluation of the effect of Medicago sativa on Lipid Profile and Iron Indices in Healthy Volunteers Evaluation of the effect of Medicago sativa on Lipid Profile and Iron Indices in Healthy Volunteers
Iranian Journal of Pharmaceutical Sciences,
Vol. 18 No. 3 (2022),
1 July 2022
,
Page 244-252
https://doi.org/10.22037/ijps.v18.42670
Abstract
Medicago sativa (alfalfa) has a long history of traditional use. Several studies indicate that the ingestion of M. sativa reduces cholesterol absorption and atherosclerotic plaque formation in animals and has been reported to be beneficial in the treatment of hemorrhage, as a tonic after blood loss and during anemia. Because hypercholesterolemia is an important risk factor for heart diseases and anemia is a common problem in developing countries, this double-blind, placebo-controlled, randomized clinical trial was designed to evaluate the effect of alfalfa extract on lipid profile and iron indices in healthy volunteers. 19 volunteers (all male) with an average age of 35 were elected for a randomized double-blind study. These volunteers were divided into two groups for drug (9 males) and placebo (10 persons). The capsules of 250 mg were taken three times a day for two months. Blood samples were collected at baseline, one month, and two months after taking the capsules. Ferritin, TIBC (Total Iron Binding Capacity), Iron, CBC (Complete Blood Count), cholesterol, triglyceride, LDL, and HDL were determined by laboratory testing standards. After two months in the treated group, serum iron showed more increase and TIBC factor decreased more in comparison with the control group and their LDL and triglyceride decreased and HDL increased but was not statistically significant. Alfalfa ethanolic extract, with 750 mg/day can help decrease LDL and triglyceride and increase HDL, and maybe increase serum iron as an adjunctive for hypercholesterolemia and anemia treatment.
- Alfalfa
- Medicago sativa
- Iron
- Anemia
- Cholesterol
- Triglycerides
How to Cite
References
[2]. National Hospital Ambulatory Medical Care Survey: (2018) Emergency Department Summary Tables. https://www.cdc.gov/nchs/data/nhamcs/web_tables/2018-ed-web-tables-508.pdf
[3]. National Vital Statistics System – Mortality Data (2019) via CDC WONDER. https://wonder.cdc.gov/controller/datarequest/D76;jsessionid=3711BF42E14C70C1A865D0B9DD82
[4]. Bora KS, Sharma A. Phytochemical and pharmacological potential of Medicago sativa: a review. Pharm. Biol. (2011) 49: 211-220.
[5]. Duke J. Handbook of Medicinal Herbs. CRC Press, Boca Raton (1985).
[6]. DerMarderosian A, Beutler JA. Review of Natural Products. 5th ed. Facts and Comparisons, Wolters Kluwer Health, Netherlands (2008) 28-32.
[7]. Steppler HA. ICRAF and a decade of agroforestry development. In: Steppler HA and Nair PKR (eds.) Agroforestry: A Decade of Development. International Council for Research in Agroforestry, Nairobi (1987) 13–24.
[8]. Swanston SK, Day C, Bailey CJ, Flatt PR. Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetologia (1990) 33: 462–464.
[9]. Cohen BI, Mosbach EH, Matoba N, Suh SO, McSherry CK. The effect of alfalfa-corn diets on cholesterol metabolism and gallstones in prairie dogs. Lipids 1990; 25: 143–148.
[10]. Malinow MR, McLaughlin KGO, Livingston AL. Prevention of elevated cholesterolemia in monkeys by alfalfa saponins. Steroids (1977) 29: 105–110.
[11]. Malinow MR, McNulty WP, Houghton DC, Kessler S, Stenzel P, Goodnight SHJ, Bardana EJJ, Palotay JL, McLaughlin P, Livingston AL. Lack of toxicity of alfalfa saponins in Cynomolgus macaques. J. Med. Primatol. (1982) 11: 106–118.
[12]. Story JA, LePage SL, Petro MS, West LG, Cassidy MM, Lightfoot FG, Vahouny GV. Interactions of alfalfa plant and sprout saponins with cholesterol in vitro and in cholesterol-fed rats. Am. J. Clin. Nutr. (1984) 39: 917–929.
[13]. Molgaard J. von Schenck H, Olsson AG. Alfalfa seeds lower low density lipoprotein cholesterol and apolipoprotein B concentrations in patients with type II hyperlipoproteinemia. Atheroscler. (1987) 65: 173-179.
[14]. Farnsworth NR. Alfalfa pills and autoimmune diseases. Am. J. Clin. Nutr. (1995) 62: 1026–1028.
[15]. Khaleel AE, Gad MZ, El-Maraghy SA, Hifnawy MS, Abdel-Sattar E. Study of hypocholesterolemic and antiatherosclerotic properties of Medicago sativa L. cultivated in Egypt. Food Drug Anal. (2005) 13: 212–218.
[16]. Jdidi H, Kouba FG, Aoiadni N, Abdennabi R, Turki M, Makni-Ayadi F and El Feki A. Effects of estrogen deficiency on liver function and uterine development: assessments of Medicago sativa's activities as estrogenic, anti-lipidemic, and antioxidant agents using an ovariectomized mouse model. Arch. Physiol. Biochem. (2021) 127(2): 170-181.
[17]. Seida A, Hefnawy H, Abou-Hussein D, Mokhtar FA, Abdel-Naim A. Evaluation of Medicago sativa sprouts as antihyperlipidemic and antihyperglycemic agent. Pak. J. Pharm. Sci. (2015) 28(6): 2061-2074.
[18]. Amaro-Terrazos JZ, Iparraguirre ME and Isla-Ponciano PC. Effect of consumption of alfalfa extract (Medicago sativa) on induced iron deficiency anemia in mice (Mus musculus). Revista de Salud Pública (2020) 20: 730-734.
- Abstract Viewed: 303 times
- IJPS- Vol 18- Issue 3- Page 244-252 Downloaded: 119 times